Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 428-434

  Bubalo, Joseph S ^a   Munar, Myrna Y ^b   Cherala, Ganesh ^b   Hayes Lattin, Brandon ^a   Maziarz, Richard ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIOSTASIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL ASSAY; DAPTOMYCIN; ETHNIC GROUPS; FEMALE; FEVER; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OBESITY, MORBID; SEX CHARACTERISTICS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 59749092290     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00943-08     Document Type: Article

References (32)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Anonymous. 2003. Cubicin (daptomycin) product information. Cubist Pharmaceuticals Inc., Lexington, MA.
3. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
4. Bhavnani, S. M., P. G. Ambrose, F. B. Oleson, and G. L. Drusano. 2006. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-655.
5. Cha, R., W. J. Brown, and M. J. Rybak. 2003. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 47:3960-3963.
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
8. Critchley, I. A., D. C. Draghi, D. F. Sahm, C. Thornsberry, M. E. Jones, and J. A. Karlowsky. 2003. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. 51:639-649.
9. Dandekar, P. K., P. R. Tessier, P. Williams, C. H. Nightingale, and D. P. Nicolau. 2003. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411.
10. DeRyke, C. A., C. Sutherland, B. Zhang, D. P. Nicolau, and J. L. Kuti. 2006. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob. Agents Chemother. 50:3529-3534.
11. Dvorchik, B., R. D. Arbeit, J. Chung, S. Liu, W. Knebel, and H. Kastrissios. 2004. Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 48:2799-2807.
12. Dvorchik, B., and D. Damphousse. 2004. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J. Clin. Pharmacol. 44:612-620.
13. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
14. Dvorchik, B. H., and D. Damphousse. 2005. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J. Clin. Pharmacol. 45:48-56.
15. Fenton, C., G. M. Keating, and M. P. Curran. 2004. Daptomycin. Drugs 64:445-455.
16. Godwin, J. E. 2004. Neutropenia. http://www.emedicine.com/med/ topic1640.htm. Accessed 24 December 2004.
17. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716.
18. Jaksic, B., G. Martinelli, J. Perez-Oteyza, C. S. Hartman, L. B. Leonard, and K. J. Tack. 2006. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. 42:597-607.
19. Kreft, B., C. de Wit, R. Krech, R. Marre, E. Schulz, and K. Sack. 1990. Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J. Antimicrob. Chemother. 25:635-643.
20. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, D. Roth, et al. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130:461-470.
21. Levey, A. S., J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, R. J. Hogg, R. D. Perrone, J. Lau, and G. Eknoyan. 2003. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139:137-147.
22. Pai, M. P., J. P. Norenberg, T. Anderson, D. W. Goade, K. A. Rodvold, R. A. Telepak, and R. C. Mercier. 2007. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 51:2741-2747.
23. Pizzo, P. A., K. J. Robichaud, F. A. Gill, F. G. Witebsky, A. S. Levine, A. B. Deisseroth, D. L. Glaubiger, J. D. Maclowry, I. T. Magrath, D. G. Poplack, and R. M. Simon. 1979. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am. J. Med. 67:194-200.
24. Rea, D. J., J. K. Heimbach, J. P. Grande, S. C. Textor, S. J. Taler, M. Prieto, T. S. Larson, F. G. Cosio, and M. D. Stegall. 2006. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 70:1636-1641.
25. Rolston, K. V. 2004. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin. Infect. Dis. 39(Suppl. 1):S44-S48.
26. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
27. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
28. Salazar, D. E., and G. B. Corcoran. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84:1053-1060.
29. Vance-Bryan, K., T. A. Larson, J. C. Rotschafer, and J. P. Toscano. 1992. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 36:2334-2337.
30. Viscoli, C., O. Varnier, and M. Machetti. 2005. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin. Infect. Dis. 40(Suppl. 4):S240-S245.
31. Wise, R., T. Gee, J. M. Andrews, B. Dvorchik, and G. Marshall. 2002. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33.
32. Woodworth, J. R., E. H. Nyhart, Jr., G. L. Brier, J. D. Wolny, and H. R. Black. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 36:318-325.